MDMB-CHMICA

MDMB-CHMICA
Legal status
Legal status	CA: Schedule II; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B; US: Schedule I; UN: Psychotropic Schedule II; Illegal in Austria, China, Brazil, Croatia, Denmark, Estonia, Finland, Greece, Hungary, Latvia, Lithuania, Luxembourg, Norway, Poland, Turkey, Sweden and Switzerland;
Identifiers
	IUPAC name Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]formamido}-3,3-dimethylbutanoate;
CAS Number	1971007-95-0 ;
PubChem CID	125181404;
ChemSpider	34450863;
UNII	X6JI7EA6EJ;
KEGG	C22787;
Chemical and physical data
Formula	C23H32N2O3
Molar mass	384.520 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)[C@@H](NC(=O)c1cn(CC2CCCCC2)c3ccccc13)C(C)(C)C;
	InChI InChI=1S/C23H32N2O3/c1-23(2,3)20(22(27)28-4)24-21(26)18-15-25(14-16-10-6-5-7-11-16)19-13-9-8-12-17(18)19/h8-9,12-13,15-16,20H,5-7,10-11,14H2,1-4H3,(H,24,26)/t20-/m1/s1; Key:SRJKCVHWIDFUBO-HXUWFJFHSA-N;

MDMB-CHMICA^[3] is an indole-based synthetic cannabinoid that is a potent agonist of the CB₁ receptor and has been sold online as a designer drug.^[2]^[4]^[5]^[6] While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.^[7]

^ "Substance Details MDMB-CHMICA". Retrieved 2024-01-22.
^ ^a ^b Cite error: The named reference EMCDDA was invoked but never defined (see the help page).
^ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325.
^ "MDMB-CHMICA". Cayman Chemical. Retrieved 29 June 2015.
^ "MDMB-CHMICA". Southern Association of Forensic Scientists. Retrieved 29 June 2015.
^ Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, et al. (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797. S2CID 31838655.

[1] "Substance Details MDMB-CHMICA". Retrieved 2024-01-22.

[EMCDDA-2] Cite error: The named reference EMCDDA was invoked but never defined (see the help page).

[3] Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325.

[4] "MDMB-CHMICA". Cayman Chemical. Retrieved 29 June 2015.

[5] "MDMB-CHMICA". Southern Association of Forensic Scientists. Retrieved 29 June 2015.

[6] Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.

[7] Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, et al. (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797. S2CID 31838655.

[1]

[2]

[3]

[4]

[5]

[6]

[7]